Aignostics raises USD 34 million in Series B financing

Berlin — YPOG has advi­sed global arti­fi­cial intel­li­gence (AI) company Aigno­stics on its recent $34 million Series B funding round. The round was led by ATHOS, with invest­ments from Mayo Clinic and growth funding from HTGF. Aigno­stics also recei­ved support from exis­ting inves­tors inclu­ding Welling­ton Part­ners, Boeh­rin­ger Ingel­heim Venture Fund, CARMA Fund and the VC Fund Tech­no­logy mana­ged by IBB Ventures. To date, Aigno­stics has raised over $55 million, demons­t­ra­ting inves­tor confi­dence in the company’s unique AI models and well-defi­­ned commer­cial stra­tegy. Aigno­stics was foun­ded in 2018 and emer­ged in 2020 as a spin-off from Charité and the Berlin Insti­tute of Health. The AI company trans­forms complex multi­mo­dal patho­lo­gi­cal data into valuable insights. Follo­wing the closing of the latest funding round, Aigno­stics plans to deve­lop new product offe­rings for biophar­maceu­ti­cal custo­mers, drive growth in the US and deve­lop advan­ced basic models for patho­logy in colla­bo­ra­tion with the Mayo Clinic. The new funding will streng­then Aigno­stics’ capa­bi­li­ties in target funding, trans­la­tio­nal rese­arch and compa­n­ion diagno­stics (CDx) and support various stra­te­gic initia­ti­ves. “2024 was a pivo­tal year for us, which included an important stra­te­gic colla­bo­ra­tion with Bayer and the launch of our first basic model, RudolfV,” said Viktor Matyas, CEO and co-foun­­der of Aigno­stics. “With Rudolf, we have gained the ability to rapidly deve­lop cost-effec­­tive algo­rithms that can be trans­fer­red to the real world. With this new round of funding, we are turning our most popu­lar algo­rithms into products that will help usher in an era of truly gene­ra­lizable AI for compu­ta­tio­nal patho­logy.” About Aigno­stics

Aigno­stics is an arti­fi­cial intel­li­gence (AI) company that turns complex multi­mo­dal patho­logy data into trans­for­ma­tive insights. By combi­ning proprie­tary access to multi­mo­da­lity clini­cal data, indus­­try-leading tech­no­lo­gies and rigo­rous science, Aigno­stics deve­lops world-class products and services for the next gene­ra­tion of precis­ion medi­cine. Through colla­bo­ra­tion with its biopharma part­ners, Aigno­stics supports drug disco­very, trans­la­tio­nal rese­arch, clini­cal trials and CDx deve­lo­p­ment. Foun­ded in 2018, Aigno­stics is a spin-off of Charité Berlin, one of the largest and most renow­ned univer­sity hospi­tals in the world. Aigno­stics is funded by leading inves­tors and has offices in Berlin and New York. www.aignostics.com.

Advi­sor Aigno­stics: YPOG

Dr. Martin Scha­per (Lead, Corporate/Transactions), Part­ner, Berlin Dr. Jonas von Kalben (Tran­sac­tions), Senior Asso­ciate, Berlin, Anja Schind­ler (Tran­sac­tions), Senior Asso­ciate, Berlin, Bene­dikt Kreu­der (Tran­sac­tions), Senior Asso­ciate, Berlin, Dr. Jacob Schrei­ber (Tran­sac­tions), Senior Asso­ciate, Munich About YPOG
YPOG is a specia­list law firm for tax and commer­cial law, active in the core areas of funds, tax, banking + finance and tran­sac­tions. The YPOG team advi­ses a wide variety of clients.

These include emer­ging tech­no­logy compa­nies and family-run medium-sized enter­pri­ses as well as corpo­ra­ti­ons and private equity/venture capi­tal funds. YPOG is one of the leading addres­ses for venture capi­tal, private equity and fund struc­tu­ring in Germany. Today, YPOG employs more than 150 expe­ri­en­ced lawy­ers, tax consul­tants, tax specia­lists and a notary in four offices in Berlin, Hamburg, Colo­gne and Munich. www.ypog.de